Newsroom
Dec 15,2022
Avirmax CMC Inc. Successfully Manufactured and Delivered to a Client the First Lot of rAAV Drug Product for a Monkey Toxicology Study
HAYWARD, Calif., Dec. 15, 2022 — Avirmax CMC Inc. (ACI), a global leader in recombinant adeno associated vector (rAAV) bioprocess development and manufacturing, using a recombinant baculovirus Sf9 cell (rBV-Sf9-AAV) system, has manufactured, tested and released its first batch of rAAV product for use in monkey toxicology and pharmacology studies for an ocular indication.
Oct 31,2022
Avirmax CMC Inc. Received License for cGMP Gene Therapy Vector Production by the California Department of Public Health
HAYWARD, Calif., Oct. 31, 2022 — Avirmax CMC Inc., a global leader in recombinant adeno associate virus vector (rAAV) innovation and manufacturing process development, using a recombinant baculovirus Sf9 (rBV-Sf9-AAV) system, has completed its brand-new facility in Hayward, CA (San Francisco Bay Area). The facility has received cGMP license approval by the California Department of Public Health (CDPH)-Food & Drug Branch, for the production of rAAV drug products for use in clinical investigations.
Oct 7,2022
Avirmax Inc. Announces Issuance of U.S. Patent Covering Catalysis Deactivated Angiotensin-Converting Enzyme 2 (ACE2) Variants for Treatment of Beta Group SARS-COV Viral Infection
HAYWARD, Calif., Oct. 7, 2022 — Avirmax Inc.(www.avirmax.com), a company focused on delivering protein therapeutics via recombinant adeno-associated viral (rAAV) vectors announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,453,869, which is directed to the composition and methods related to the use and administration of catalysis deactivated angiotensin-converting enzyme 2 (ACE2) for preventing SARS-COV-1 and SARS-COV-2 infection.
Dec 9,2021
Avirmax Inc. Announces Publication in Genetic Engineering & Biotechnology News
-Overcoming Biosafety Challenges posed by Viral Vectors through Bac-to-AAV, 2D-HPLC, QbD, LC-MS/MS, and other Technologies
HAYWARD, CA [December 9, 2021]—Dr. Shawn (Shengjiang) Liu, President and CEO of Avirmax, Inc., in San Francisco Bay Area, today announced technical contributions and collaboration with Dr. Kathy Liszewski, Assistant Professor of Medicine at Washington University School of Medicine in St. Louis.
Oct 18,2021
Avirmax Presents Simple and Robust Technology Platform for AAV Production
Presentation Detailing Bac-to-AAV Sf9 Platform High-Titer, Downstream Purity and Safety
HAYWARD, Calif., [October 18, 2021]—Dr. Shawn (Shengjiang) Liu, President and CEO of Avirmax, Inc., a San Francisco Bay Area Gene Therapy company, presented “A Simple and Robust rAAV Manufacturing System to Achieve High Titer and Quality Gene Therapy Vectors” during the BioProcessing International Conference at the Boston Convention and Exhibition Center and online.